Posted by Michael Wonder on 07 May 2020
Ascentage Pharma's core drug candidate HQP1351 granted fast track designation by the US FDA, marking another milestone in its development
7 May 2020 - Ascentage Pharma today announced that the US FDA has granted HQP1351, the Company's core drug candidate, a fast track designation for the treatment of patients with chronic myeloid leukaemia with certain genetic mutations who have failed to respond to treatments with existing tyrosine kinase inhibitors.
This is the first FTD obtained by Ascentage Pharma, and it marks another milestone for HQP1351 following its recent orphan drug designation by FDA.
